Holen Sie sich die Stockscreener-App
2.575
1.15%
-0.035
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.61
Offen:
$2.62
24-Stunden-Volumen:
8.10M
Relative Volume:
1.64
Marktkapitalisierung:
$662.57M
Einnahmen:
$403.14M
Nettoeinkommen (Verlust:
$-22.68M
KGV:
-12.29
EPS:
-0.2095
Netto-Cashflow:
$-13.09M
1W Leistung:
-1.90%
1M Leistung:
-5.15%
6M Leistung:
-17.31%
1J Leistung:
+109.76%
1-Tages-Spanne:
$2.52
$2.77
1-Wochen-Bereich:
$2.52
$2.9085
52-Wochen-Spanne:
$0.6925
$4.175
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Firmenname
Esperion Therapeutics Inc
Sektor
Telefon
734-887-3903
Adresse
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.58 | 670.28M | 403.14M | -22.68M | -13.09M | -0.2095 |
TAK
Takeda Pharmaceutical Co Adr
|
18.20 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
118.04 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.935 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.68 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
554.19 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-25 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-18 | Eingeleitet | Goldman | Neutral |
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-01 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Hochstufung | BofA Securities | Underperform → Buy |
| 2023-03-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Fortgesetzt | BofA Securities | Neutral |
| 2023-02-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-19 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-09 | Herabstufung | Goldman | Neutral → Sell |
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-10 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Underweight |
| 2020-08-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-24 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-16 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-29 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Hochstufung | Goldman | Sell → Neutral |
| 2019-03-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Bestätigt | Needham | Strong Buy |
| 2018-12-13 | Eingeleitet | Goldman | Sell |
| 2018-10-29 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Eingeleitet | BTIG Research | Buy |
| 2018-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-07-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
Alle ansehen
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
Ann Arbor pharmaceutical company acquires nasal spray treatment manufacturer - MLive.com
Esperion Therapeutics, Inc. $ESPR Shares Purchased by JPMorgan Chase & Co. - MarketBeat
ESPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Esperion Therapeutics, Inc. (ESPR) latest stock news and headlines - Yahoo Finance Singapore
Esperion Therapeutics, Inc. (ESPR) stock price, news, quote and history - Yahoo Finance UK
Esperion Completes Corstasis Acquisition, Expands Cardiovascular Portfolio - The Globe and Mail
Esperion sells Japan royalty rights for $50 million to Athyrium By Investing.com - Investing.com Canada
Esperion (ESPR) highlights inclusion of bempedoic acid in 2026 ACC/AHA dyslipidemia guidelines - msn.com
Athyrium Capital Management and Esperion Therapeutics Inc. (NASDAQ: ESPR) have signed a Japanese royalty financing agreement worth $50 million - Bitget
Esperion Therapeutics Enters First Amendment To Credit Agreement On April 2, 2026SEC Filing - TradingView
Esperion Therapeutics, Athyrium Capital Management Sign $50 Million Japan Royalty Financing - marketscreener.com
Esperion Therapeutics Inc. has successfully secured financing, which will be specifically used to support its acquisition of Corstasis Therapeutics. - Bitget
Esperion Therapeutics Inc. (ESPR) has entered into a new financial arrangement with the Athyrium Fund. - Bitget
Esperion Adds $25 Million Term Loans, Sells $50 Million Otsuka Royalties to Fund Corstasis Buy - TradingView
Esperion (ESPR) acquires Corstasis, adds $25M term loan and $50M royalty sale - Stock Titan
Esperion sells Japan royalty rights for $50 million to Athyrium - investing.com
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics - The Manila Times
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) - The Manila Times
Esperion completes acquisition of Corstasis Therapeutics - investing.com
Athyrium Capital Management and Esperion Enter Into $50 - globenewswire.com
Esperion Therapeutics ranks 88 among 300 on Americas Fastest Growing Companies list - Traders Union
Zacks Research Has Negative Forecast for ESPR Q2 Earnings - MarketBeat
Esperion Presents New Data from CLEAR Outcomes Highlighting Value of Bempedoic Acid at ACC.26 - dicardiology.com
Esperion Therapeutics, Inc. completed the acquisition of Corstasis Therapeutics Inc. - marketscreener.com
New Analyst Updates: $9 and $16 Price Targets on Esperion Therapeutics Signal Major Upside From $2.63 - Moomoo
Q4 EPS Estimate for Esperion Therapeutics Raised by Analyst - MarketBeat
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing - citybiz
Esperion Therapeutics Inc (ESPR) strengthens business outlook amid strategic agreements - MSN
Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference - Bitget
Esperion to acquire Corstasis for $75M upfront payment - MSN
Esperion Therapeutics (NASDAQ:ESPR) Trading Up 9.7%Here's What Happened - MarketBeat
Investors can watch Esperion at Needham's virtual healthcare event - Stock Titan
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16 - Moomoo
US Market Wrap: Can Esperion Therapeutics Inc outperform under higher oil prices2026 Technical Overview & Free Community Consensus Stock Picks - baoquankhu1.vn
Needham Virtual Healthcare Conference features Esperion Therapeutics at 25th anniversary session - Traders Union
Esperion reports bempedoic acid cut ischemic stroke risk by 22% - Investing.com Canada
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL (bempedoic acid) at the American College of Cardiology's Annual Scientific Session 2026 - Bitget
Esperion Therapeutics unveils new CLEAR Outcomes data on NEXLETOL at ACC Annual Scientific Session - Traders Union
Esperion Showcases New Data from CLEAR Outcomes - globenewswire.com
Tech Rally: Is Esperion Therapeutics Inc in a bullish channelM&A Rumor & Growth Focused Entry Reports - baoquankhu1.vn
Vanguard (ESPR) Amendment: Reports zero ESPR common shares after internal realignment - Stock Titan
Esperion Therapeutics (NASDAQ:ESPR) Share Price Crosses Below 200 Day Moving AverageTime to Sell? - MarketBeat
Esperion shares rise 8% after revenue tops forecasts and acquisition announced - MSN
Dip Buying: Does Esperion Therapeutics Inc align with a passive investing strategy2026 Sector Moves & Free Reliable Trade Execution Plans - baoquankhu1.vn
Esperion acquires Enbumyst maker Corstasis - MSN
Esperion Therapeutics prices $75M public offering - MSN
Esperion (ESPR) Highlights Inclusion of Bempedoic Acid in 2026 ACC/AHA Dyslipidemia Guidelines - Insider Monkey
ESPR SEC FilingsEsperion Therape 10-K, 10-Q, 8-K Forms - Stock Titan
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down - MSN
Finanzdaten der Esperion Therapeutics Inc-Aktie (ESPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Esperion Therapeutics Inc-Aktie (ESPR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Koenig Sheldon L. | President and CEO |
Mar 17 '26 |
Sale |
2.72 |
25,578 |
69,547 |
2,172,699 |
| Halladay Benjamin | Chief Financial Officer |
Mar 17 '26 |
Sale |
2.71 |
6,424 |
17,377 |
713,602 |
1.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):